(AOF) – Spineway achieved a turnover of 3.1 million euros in the first quarter of 2024, an increase of 28%. The specialist in innovative implants for the treatment of severe spinal pathologies (spine) specifies that this purely organic growth (without scope effect) “testifies to the good sales dynamics of the Group in its two main zones, Europe and Latin America, which represent 85% of turnover over the quarter. This progression is driven by sales of Premium ranges (in particular Veos, Distimp range) over the quarter.
This increase in sales “will allow the group to continue its investments in order to obtain new approvals and CE/MDR certifications for its product ranges”, announces Spineway. The group “confirms its ambition to become a major player in less invasive spine treatments”.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.